Ramatroban

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Ramatroban (INN) is a thromboxane receptor antagonist indicated for the treatment of coronary artery disease.^[1] It has also been used for the treatment of asthma.^[2]

It was developed by the German pharmaceutical company Bayer AG and is co-marketed in Japan by Bayer and Nippon Shinyaku Co. Ltd. under the tradename Baynas.

References

↑ Fiedler VB, Seuter F, Perzborn E (1990). “Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease”. Stroke. 21 (12 Suppl): IV149–51. PMID 2260140. Unknown parameter |month= ignored (help)
↑ Endo S, Akiyama K (1996). “[Thromboxane A2 receptor antagonist in asthma therapy]”. Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952. Unknown parameter |month= ignored (help)

Template:Ja icon Baynas

Template:Asthma and copd rx

Template:WH Template:WS

[pmid2260140-1] Fiedler VB, Seuter F, Perzborn E (1990). “Effects of the novel thromboxane antagonist Bay U 3405 on experimental coronary artery disease”. Stroke. 21 (12 Suppl): IV149–51. PMID 2260140. Unknown parameter |month= ignored (help)

[pmid8950952-2] Endo S, Akiyama K (1996). “[Thromboxane A2 receptor antagonist in asthma therapy]”. Nippon Rinsho (in Japanese). 54 (11): 3045–8. PMID 8950952. Unknown parameter |month= ignored (help)

[1]

[2]